DV
Dividend Vision

BBIO — BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BBIO)

Total return is 189.9% over the past 7.1 years, 5.1 points behind SPY at 195.0%. Its deepest 1-year drawdown was 20.2%.

BridgeBio Pharma is a single-stock equity holding in the healthcare sector that focuses on innovative drug development and therapeutic solutions. As an individual company stock rather than a diversified fund, it does not currently pay distributions and carries no reported expense ratio typical of traditional ETFs. This holding appeals primarily to growth-oriented investors seeking exposure to the pharmaceutical innovation space, rather than to income-focused dividend investors.

BBIO key facts

Asset type
Stock
Asset class
Equity
Inception date
06/27/2019
Distribution frequency
None
Last close
$79.86
Market cap
$15,611,629,568
Average volume
3094000.0
Beta
0.983
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.56